anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Substance use disorder (SUD) is problem among women military Veterans, especially younger ones. The goal of this study was to examine the efficacy a gender-focused model of SUD treatment (A Woman's Path to Recovery, WPR) compared to an evidence-based active comparator that is not gender-specific (12-Step Facilitation, 12SF), in a sample of for women Veterans. The investigators randomized 66 women Veterans, ages 18-65, who were diagnosed with current SUD and used substances in the last 90 days. The treatment phase was 12 weekly individual therapy sessions and all participants could also obtain treatment-as-usual (any other treatments they chose to attend). Assessments were conducted at baseline, end of treatment and 3-month follow up. Sample size was based on power analysis (an effect of .80 at a .05 level of significance). The primary outcome variable was substance use, with various secondary outcomes also studied (e.g., psychosocial functioning, psychiatric symptoms, coping skills, 12-step attendance). Urinalysis / breathalyzer (biological measures) were also included to validate substance use self-report. The investigators hypothesized that participants in the experimental condition (WPR) would have more positive outcomes on both primary and secondary variables compared to those in the comparison condition (12SF). The investigators also hypothesized that WPR patients would increase coping skills more and 12SF would increase 12-step attendance more, relative to the other condition.
PURPOSE:To prevent the elution of decenoic acid and obtain the titled pharmaceutical having improved preservation quality and handleability, by adding a cyclodextrin mixture to gelatin to be a film-forming agent, adding and blending royal jelly with the resultant blend solution, pouring the blend into a dispersion medium oil and microencapsulating the above-mentioned blend. CONSTITUTION:Gelatin which is a film-forming agent is thoroughly blended with cyclodextrin mixture in the presence of water at, e.g. 60 deg.C, and royal jelly is then added to the resultant blend solution and further blended while stirring. The obtained blend solution is then poured into a dispersion medium oil, e.g. soybean oil, etc., heated at 60 deg.C, stirred, dispersed, microencapsulated and then cooled to, e.g. 10 deg.C, to remove the oil. The resultant microcapsules are dehydrated with an alcohol, etc., and dried to afford the titled microcapsule pharmaceutical of 150-5 mesh particle size with a smooth and beautiful surface.
BACKGROUND: The SUPV3L1 gene encodes ATP-dependent RNA helicase SUPV3L1, which is a part of the mitochondrial degradosome complex or SUV3. SUPV3L1 unwinds secondary structures of mitochondrial RNA (mtRNA) and facilitates the degradation of mtRNA molecules. A nonsense homozygous variant in the SUPV3L1 gene was recently associated with mitochondrial disease. Our study presents the second documented case of SUPV3L1 pathology in humans.
METHODS: Whole-genome sequencing was performed on the NovaSeq 6000 platform using pair-end reading. Data analysis was performed with an in-house developed pipeline.
RESULTS: The 17-year-old female patient exhibited a diverse array of symptoms, including ataxia, spastic paraparesis, cognitive deficit, optic atrophy, and horizontal gaze-evoked nystagmus. Early onset of symptoms, such as ataxic gait and nystagmus, was noted, with subsequent progression of neurological manifestations. At the time of the observation, the proband had extensive regions of hypopigmented skin patches on the body and extremities, which have progressed over time. Whole-genome sequencing revealed compound heterozygous variants in the SUPV3L1 gene: c.272-2A>G and c.1924A>C; p.(Ser642Arg). RNA analysis demonstrated splicing changes attributable to the c.272-2A>G variant. ELISA assay showed increased Complex I content in the patient's fibroblasts. This case underscores the phenotypic diversity associated with SUPV3L1 mutations, emphasizing the importance of considering mitochondrial RNA helicase dysfunction in the differential diagnosis of neurodegenerative disorders. Further elucidation of the molecular mechanisms underlying SUPV3L1-associated pathology may provide valuable insights into targeted therapeutic interventions.
Over the past several decades, 5-fluorouracil based chemoradiation has been the cornerstone for the treatment of locally advanced non-operable pancreatic cancer. However, the survival of these patients is disappointing. The majority of the patients suffer either local progression or metastatic disease. With the availability of Capecitabine, a few pilot studies showed the the drug is convenient, tolerable and safe in combination with radiation therapy. Capecitabine demonstrated its superior anti-tumor activity with 14 months of median survival. However, these are small Phase I studies and the survival benefit needs to be further validated with larger studies. Epidermal growth factor receptor (EGFR) has been implicated in tumor growth and angiogenesis. Inhibiting EGFR by Tarceva has demonstrated effective treatment in metastatic pancreatic cancer. Anti-epidermal growth factor therapy in combination with radiotherapy has been demonstrated efficacious in other solid tumors such as head and neck cancer. We hypothesize that the combination of Tarceva and Capecitabine has synergistic anti-tumor effect. Hence, improvement of median survival could be potentially achieved with this novel combination.
Method: The research was completed in Kahramanmaraş Necip Fazıl City Hospital with 100 patients, 50 of whom were in the Study Group (WG) and 50 were in the Control Group (KG). The patients in CG were given warm water to drink at the 2nd hour after surgery. On the other hand, patients in KG were allowed to drink warm water after bowel sounds started and gas was produced. Patients in both groups were 2,4,8,12 after surgery. hours were evaluated in terms of GIS functions. Statistical analysis was done in SPSS 22.0 for Windows package program. A p\<0.05 value was accepted for statistical significance.
Received i.v. PCA with the same volume of solution containing 1250 µg fentanyl plus 120 mg of nefopam in normal saline (fentanyl 12.5 µg/ml and nefopam 1.2 mg/ml).
Oral contraceptives will be taken daily for 24 days along with placebo (oral) once daily for cycle 1. During cycle 3, cannabidiol will be taken once daily along with OCPs.
The utility model relates to a herbal additive which is intended to supplement the normal diet and which is a concentrated source of substances with a nutritional and / or physiological effect. The food additive has the following composition: peppermint (Mentha pipegita L.) 30 mg, hawthorn (Crataegus Monogyna) 120 mg, valerian (Valeriana officinalis L.) 100 mg and lemon balm (Melissa officinalis) 10 mg. It is suitable for conditions of anxiety, tension and nervousness. The effects of the combination of peppermint, hawthorn, valerian, and balm are complementary. It has a beneficial effect on the nervous and cardiovascular system. The food additive contributes to a better sleep and mood, as well as the maintenance of mental balance and well-being. 1 claim
The aim of this study was to investigate the effects of strengthening exercises and manual therapy on bleeding frequency, pain, range of motion, muscle strength, arm circumference, joint health, functionality and quality of life in the physiotherapy and rehabilitation of hemophilic arthropathy of the elbow. Seventeen adolescent and young adult hemophilic individuals aged 12-30 years with elbow arthropathy were included in the study. The individuals were divided into the two groups via simple randomisation as Manuel Therapy and Exercise Group (MTEG) and Home Exercise Group (HEG). The individuals in HEG were given strengthening exercises as a home program. Those in the MTEG were applied manual therapy by the physiotherapist and were given supervised strengthening exercises. All treatments were performed 3 times a week for 5 weeks totally 15 sessions. Frequency of bleeding was evaluated with number of bleeding in the last 5 weeks. Numerical Pain Scale was used for activity and resting pain. Range of motion and muscle strength were measured with universal goniometer and digital dynamometer, respectively. The Quick-DASH questionnaire and Oxford Elbow Score were used for the functionality of the upper extremity and quality of life, respectively. The joint health status was evaluated with Hemophilia Joint Health Score-Elbow Point and Hospital for Special Surgery-Elbow Scoring System. Evaluations were made by the same physiotherapist before and after treatment.
The invention discloses an acid-activated antitumor peptide, and belongs to the technical field of biological medicines. The structure of the anti-tumor peptide is rich in leucine and histidine, and simultaneously contains a small amount of glutamic acid and lysine. The general formula of the structure is K  x  L  7  H  n  E  m  X, wherein X =0, 1, 2; n =4, 5, 6; m =0, 1, 2; x is L, W, F or I at the carbon end of the peptide chain. The anti-tumor peptide has simple structure and low manufacturing cost. In vitro acid-activated antitumor experiments, hemolytic experiments and scanning electron microscope experiments show that the antitumor peptides have acid-activated antitumor activity on various cancer cells and have low hemolytic toxicity, and in addition, the antitumor peptides can rapidly kill the tumor cells through a membrane rupture mechanism so as to ensure that the antitumor peptides are openedHas great application potential in the aspects of developing novel anti-tumor drugs and resisting multidrug resistance. Therefore, the antitumor polypeptide has good application prospect in the aspect of preparing clinical application medicaments.
There is no specific antidote for overdose with VIMPAT. Standard decontamination procedures should be followed. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of patient. A Certified Poison Control Center should be contacted for up to date information on the management of overdose with VIMPAT.

Standard hemodialysis procedures result in significant clearance of VIMPAT (reduction of systemic exposure by 50% in 4 hours). Hemodialysis has not been performed in the few known cases of overdose, but may be indicated based on the patient's clinical state or in patients with significant renal impairment.
Participants received chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10 days. Participants on azacitidine received 75 mg/m\^2 daily by SC or IV injection for 7 days. Participants on LoDAC or azacitidine treatment continued until they met discontinuation criteria. Participants on MEC chemotherapy received mitoxantrone 8 mg/m\^2 daily by IV for 5 days, etoposide 100 mg/m\^2 daily by IV for 5 days and cytarabine 1000 mg/m\^2 daily by IV for 5 days (days 1-5). Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m\^2 daily by SC/IV for 5 days (days 1-5), fludarabine 30 mg/m\^2 daily by IV for 5 days (days 2-6), cytarabine 2000 mg/m\^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m\^2 daily by IV for 3 days (days 2-4). Participants receiving MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15.
Primary varicella infection, or chickenpox, can be devastating to HIV-infected children because complications occur at higher rates in immunocompromised hosts. Current passive prophylaxis measures with varicella-zoster immune globulin are suboptimal because administration must be repeated for each exposure during the child's lifetime and timely notification of exposure is not always possible. Since Varivax has been licensed for routine vaccination of healthy individuals, it must be determined whether this vaccine can be safely administered to HIV-infected children.

Thirty-six children who are varicella zoster virus (VZV)-naive (treatment group) receive Varivax at Weeks 0 and 12, with a possible boost at Week 52 if the patient is still seronegative for VZV and cytomegalovirus infection. Twenty children who have a history of wild-type varicella exposure within the past year (control group) receive no study treatment. All patients are either asymptomatic or mildly symptomatic for HIV infection. Patients make 12-14 visits to the clinic. \[AS PER AMENDMENT 9/9/99: This study has been reorganized into two cohorts (asymptomatic and symptomatic). In the asymptomatic cohort, accrual has been completed with 40 patients in Treatment Group I and 19 in the control group. This phase of the study demonstrated that Varivax was well tolerated in 48 HIV-infected children with asymptomatic disease. The symptomatic cohort includes Treatment Groups II and III, each with 30 patients. The first 10 patients from Group II are monitored for 42 days following the first dose of vaccine before the remaining 20 are accrued. Once the first 10 patients in Group II have been evaluated with acceptable toxicity and immunologic profiles, the remaining 20 Group II and the first 10 Group III patients are enrolled. The first 10 Group III patients are also followed for acceptable toxicity and immunologic response before accrual of the remaining 20 Group III patients.\]
1,084,071. Artificial teeth. DOW CORNING CORPORATION. Feb. 11, 1965 [April 27, 1964], No. 6029/65. Heading A5R. [Also in Divisions B2, B5 and C3] Thermoplastic resins (including thermoplastic cellulose derivatives) are bonded to siliceous materials, such as glass sheets or fabrics, asbestos, ceramics, or silicone elastomers, or to metals such as aluminium or steel, or metal oxides, by bringing the components together after having rendered the surface of one of them plastic, as by heating or applying a solvent, and after applying to one component a polymeric organo-silicon material having per molecule at least one silyl group at least one silicon atom being attached to oxygen, a hydrolysable group, a hydroxyl group or a hydrocarbon or halohydrocarbon radical of less than 10C atoms, the polymer having a molecular weight of at least 2000, preferably 10-20000, and containing at least three siliconbonded non-halogen hydrolysable or hydroxyl groups per molecule, the polymeric material being a graft polymer of the organo-silicon group with the, or a, thermoplastic resin or polyurethane, and being applied as such, or in a volatile solvent, or in aqueous solution or emulsion. The themoplastic component may be applied as a preformed layer, as an impregnant for a fabric layer or in solution as a coating. In a modification the polymeric organo-silicon material, in solution together with the thermoplastic resin, may be admixed with the siliceous component, e.g. chopped glass fibre, to form a moulding composition Examples of thermoplastic resins usable are polythene, polypropylene, polybutylene, polyisobutylene, polystyrene, p.v.c., polyvinylidene, chloride, P.T.F.E., polytrifluoropropene, polyvinyl acetate or acrylonitrile, polyacrylates and methacrylates, polyethyleneterephthalate, poly- 1,4-butane diol isophthalate, polyamides, polycarbonates, and polyformaldehyde; cellulose acetate and ethyl cellulose are included. The silicon-bonded hydrolysable groups in the polymeric organo-silicon material may be any groups replaceable by water to form Si-OH groups, e.g. alkoxy, acyloxy, or cyano or isocyano groups. Reference is made to the bonding by the method of the invention, of porcelain teeth to thermoplastic dentures and of a liner of room temperature-vulcanizing silicon elastomer to the surface of such dentures.
The invention relates to the deposition of nanoparticles from the gas phase of the athermal plasma of a gas discharge and the subsequent attachment of said nanoparticles to the substrate particles. The invention can be used for increasing the flowability of solid bulk material. Particularly the pharmaceutical industry utilizes numerous intermediate and final products in the form of powders which cause processing problems because of the poor flowability thereof. With fine-grained materials, undesired adhesive effects occur foremost because of Van der Waals' forces. Said effects can be reduced by applying nanoparticles to the surface of the material that is to be treated. The invention is characterized by a combined process in which the nanoparticles are produced and are attached to the substrate surface. Using a non-thermal plasma additionally makes it possible to treat temperature-sensitive materials that are often used in the pharmaceutical industry.
PURPOSE: To investigate the clinical impact of plan complexity on the local recurrence-free survival (LRFS) of non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT).
METHODS: Data from 123 treatment plans for 113 NSCLC patients were analyzed. Plan-averaged beam modulation (PM), plan beam irregularity (PI), monitor unit/Gy (MU/Gy) and spherical disproportion (SD) were calculated. The γ passing rates (GPR) were measured using ArcCHECK 3D phantom with 2 %/2mm criteria. High complexity (HC) and low complexity (LC) groups were statistically stratified based on the aforementioned metrics, using cutoffs determined by their significance in correlation with survival time, as calculated using the R-3.6.1 packages. Kaplan-Meier analysis, Cox regression, and Random Survival Forest (RSF) models were employed for the analysis of local recurrence-free survival (LRFS). Propensity-score-matched pairs were generated to minimize bias in the analysis.
RESULTS: The median follow-up time for all patients was 25.5 months (interquartile range 13.4-41.2). The prognostic capacity of PM was suggested using RSF, based on Variable Importance and Minimal Depth methods. The 1-, 2-, and 3-year LRFS rates in the HC group were significantly lower than those in the LC group (p = 0.023), when plan complexity was defined by PM. However, no significant difference was observed between the HC and LC groups when defined by other metrics (p > 0.05). All γ passing rates exceeded 90.5 %.
CONCLUSIONS: This study revealed a significant association between higher PM and worse LRFS in NSCLC patients treated with SBRT. This finding offers additional clinical evidence supporting the potential optimization of pre-treatment quality assurance protocols.
Methicillin-resistant Staphylococcus aureus (MRSA) is a major human pathogen that causes various diseases. Extensive researches highlight the significant role of gut microbiota and its metabolites, particularly spermidine, in infectious diseases. However, the immunomodulatory mechanisms of spermidine in MRSA-induced bloodstream infection remain unclear. Here, we confirmed the protective effects of spermidine in bloodstream infection in mice. Spermidine reduced the bacterial load and expression of inflammatory factors by shifting the macrophage phenotype to an anti-inflammatory phenotype, ultimately prolonging the survival of the infected mice. The protective effect against MRSA infection may rely on the elevated expression of protein tyrosine phosphatase nonreceptor 2 (PTPN2). Collectively, these findings confirm the immunoprotective effects of spermidine via binding to PTPN2 in MRSA bloodstream infection, providing new ideas for the treatment of related infectious diseases.
Participants in Part 2 will only receive single dose of Treatment A2 oral Suspension (25 mg, Fasted) then Treatment B2 (Fluid Bed Granulation Tablets (5\*5 mg Tablets, Fasted) followed by Treatment C2 (Fluid Bed Granulation Tablets, 5\*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
The goal of the study is to determine whether repeatedly breathing mild bouts of low oxygen for brief periods (termed acute intermittent hypoxia (AIH)) combined with transcutaneous spinal cord stimulation (tSTIM) improves recovery of walking and strength after spinal cord injury. This idea stems from animal studies on respiration, in which investigators showed that mild AIH improves breathing in rats with spinal injuries as well as studies involving spinal cord stimulation. These studies showed that AIH induces plasticity, strengthening neural connections by increasing the production of key proteins and improving the sensitivity of spinal cord circuitry. Additional studies have shown that tSTIM may enhance function and strength for people with spinal cord injuries. The ultimate goal of this research is to assess if combining AIH and tSTIM with walking training can enhance individuals walking training greater than just AIH or tSTIM. By using low oxygen as a pre-treatment to tSTIM during walking training, functional independence and quality of life for servicemen and civilians may improve.
The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
The present invention relates to the field of veterinary medicine, more specifically to compositions and methods useful for processing animal semen for use in assisted reproduction. The invention relates to a composition for separation of spermatozoa from a semen sample, comprising at least one salt of an alkali metal and/or an alkaline earth metal, EDTA, a zwitterion buffer, silane-coated silica particles and water, said composition having a pH of 7.0- 7.35 and an osmolarity of 300-345 mOsm. Furthermore it relates to a method for preparing spermatozoa from a semen sample from a non-human animal, comprising the step of separating the spermatozoa from other semen constituents by centrifugation through a single layer of a colloid formulation. Preferably, the colloid formulation is the composition according to the invention. The invention also relates to a method for separating a sperm sub-population of interest from a semen sample from a non-human animal, comprising the steps of providing a density gradient comprising at least two layers of the composition of the invention, each layer having a different density;separating the sperm sub-populations in the semen sample by centrifugation through the density gradient; and selecting the sperm sub-population of interest. Finally, the invention relates to spermatozoa prepared with the methods of the invention and the use of such spermatozoa in artificial insemination, in vitro fertilisation or intracytoplasmic sperm injection.